Yubo International Biotech Limited
YBGJ
$0.0163
-$0.0097-37.31%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -- |
| Cost of Revenue | -- | -- | -202.38% | 4.62% | 25,480.00% |
| Gross Profit | -- | -- | -76.24% | -125.66% | -14,311.11% |
| SG&A Expenses | -18.63% | 35.76% | -21.57% | 43.46% | 42.55% |
| Depreciation & Amortization | 0.67% | -4.09% | -63.16% | 5.31% | 144.81% |
| Other Operating Expenses | -120.94% | -50.41% | -47.14% | 494.56% | -6.73% |
| Total Operating Expenses | -58.27% | 13.18% | -34.58% | 47.15% | 62.27% |
| Operating Income | 58.27% | -14.14% | 31.76% | -9,804.69% | -62.89% |
| Income Before Tax | 58.27% | -14.11% | 31.79% | -9,958.73% | -62.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 58.27% | -14.11% | 31.79% | -9,958.73% | -62.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -72.60% | -1.55% | -- | -- | -- |
| Net Income | 56.34% | -15.45% | 44.01% | -9,319.05% | -43.62% |
| EBIT | 58.27% | -14.14% | 31.76% | -9,804.69% | -62.89% |
| EBITDA | 62.95% | -16.48% | 22.79% | -1,170.47% | -58.25% |
| EPS Basic | 56.82% | 88.57% | 44.19% | -4,900.00% | -41.94% |
| Normalized Basic EPS | 56.00% | 88.24% | 51.85% | -- | -31.58% |
| EPS Diluted | 56.82% | 88.57% | 44.19% | -4,900.00% | -41.94% |
| Normalized Diluted EPS | 56.00% | 88.24% | 51.85% | -- | -31.58% |
| Average Basic Shares Outstanding | 0.00% | 900.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 900.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |